探析缬沙坦联合卡维地洛治疗慢性心衰

摘要

Objective To investigate the clinical efficacy of valsartan combined with carvedilol treatment of chronic heart failure.Methods Patients with chronic heart failure in our hospital 68 cases drawn as research subjects, depending on the random drug treatment were divided into control and experimental groups, 34 cases in each group. Among the control group using conventional methods of treatment, the experimental group is using valsartan combined with carvedilol treatment, compared two groups of patients with total efifciency, adverse reactions and cardiac function after treatment.ResultsIn contrast, the total effective rate of the experimental group 91.18% (31/34), significantly higher than the 70.59% (24/34), the difference was statistically significant (P<0.05).Conclusion The use of valsartan combined with carvedilol treatment of chronic heart failure has significant clinical efficacy, improve heart function, and no significant adverse reactions.%目的：探讨缬沙坦联合卡维地洛治疗慢性心衰的临床疗效。方法将我院收治的慢性心衰患者抽取68例作为研究对象，根据治疗药物的不同随机分为对照组和实验组，每组各34例。其中对照组采用常规方法治疗，实验组则采用缬沙坦联合卡维地洛治疗，对比两组患者的总有效率、不良反应和治疗后的心功能。结果经对比，实验组的总有效率为91.18%（31/34），高于对照组的70.59%（24/34），差异具有统计学意义（P＜0.05）。结论采用缬沙坦联合卡维地洛治疗慢性心衰具有显著的临床疗效，有效改善心功能，且无明显不良反应。